|Product||Indication||Preclinical||IND||Phase 1||Phase 2|
BIO-11006 is a ten amino acid peptide that inhibits phosphorylation of the MARCKS protein. In both In Vitro and In Vivo studies, the product has shown effects to significantly reduce mucus hyper secretion, cell inflammation, and cell motility/division.
The product has two active INDs. The respiratory IND is for COPD and ARDS, and the oncology IND is for studying safety and effect in non small cell lung cancer (NSCLC). It has been used to treat more than 300 patients in COPD during Phase 1 and 2 studies in the U.S. It was well tolerated at doses up to 125mg bid for three weeks.
The studies planned include a proof of efficacy study in stage 4 NSCLC, and in the treatment of ARDS, both of which are supported by compelling data from In Vivo animal model studies.
BIO-10901 is a nine amino acid peptide that is the major metabolite of BIO-11006. It has equal efficacy in both In Vitro and In Vivo studies as BIO-11006.